Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response
- 27 May 2021
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 35 (13) , 2119-2127
Abstract
Objective: There is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. Design: A multicentric prospective cohort study. Methods: HCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. Results: One thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7–24) months, ascites 14 (6–29) months, hepatocellular carcinoma (HCC) 17 (11–42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22–38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6–28.2) months vs. 25.4 (12.5–41.53) months, respectively (P = 0.026)]. Conclusion: The vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.Keywords
This publication has 33 references indexed in Scilit:
- Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer SurveillanceClinical Gastroenterology and Hepatology, 2017
- Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general populationJournal of Hepatology, 2016
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinomaHepatology, 2015
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trialAlimentary Pharmacology & Therapeutics, 2009
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus CoinfectionClinical Infectious Diseases, 2007
- Clinical progression of hepatitis C virus–related chronic liver disease in human immunodeficiency virus–infected patients undergoing highly active antiretroviral therapyHepatology, 2007
- Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006